US Patent

US10959996 — Methods for the treatment of abnormal involuntary movement disorders

Method of Use · Assigned to Auspex Pharmaceuticals Inc · Expires 2036-03-07 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects new dosage regimens for deuterium-substituted benzoquinoline compounds used to treat abnormal muscular activity and movement disorders.

USPTO Abstract

Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo

Patent Metadata

Patent number
US10959996
Jurisdiction
US
Classification
Method of Use
Expires
2036-03-07
Drug substance claim
No
Drug product claim
No
Assignee
Auspex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.